Results 11 to 20 of about 54,634 (147)

The Interplay of HIV-1 and Macrophages in Viral Persistence [PDF]

Frontiers in Microbiology, 2021
HIV-1 has evolved mechanisms to evade host cell immune responses and persist for lifelong infection. Latent cellular reservoirs are responsible for this persistence of HIV-1 despite the powerful effects of highly active antiretroviral therapies (HAART ...
Chynna M. Hendricks, Thaissa Cordeiro, Ana Paula Gomes, Mario Stevenson   +3 more
doaj   +3 more sources

Emerging PCR-Based Techniques to Study HIV-1 Reservoir Persistence [PDF]

Viruses, 2020
While current antiretroviral therapies are able to halt HIV-1 progression, they are not curative, as an interruption of treatment usually leads to viral rebound.
Laurens Lambrechts, Basiel Cole, Sofie Rutsaert, Wim Trypsteen, Linos Vandekerckhove   +4 more
doaj   +3 more sources

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

Nature Reviews Microbiology, 2014
Effective antiretroviral therapy (ART) blunts viraemia, which enables HIV-1-infected individuals to control infection and live long, productive lives. However, HIV-1 infection remains incurable owing to the persistence of a viral reservoir that harbours integrated provirus within host cellular DNA.
Nancie M Archin, Carolina Garrido Pavon, Natalia Soriano-Sarabia   +2 more
exaly   +4 more sources

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. [PDF]

PLoS Pathogens, 2017
Antiretroviral therapy (ART) reduces levels of HIV-1 and immune activation but both can persist despite clinically effective ART. The relationships among pre-ART and on-ART levels of HIV-1 and activation are incompletely understood, in part because prior
Rajesh T Gandhi, Deborah K McMahon, Ronald J Bosch, Christina M Lalama, Joshua C Cyktor, Bernard J Macatangay, Charles R Rinaldo, Sharon A Riddler, Evelyn Hogg, Catherine Godfrey, Ann C Collier, Joseph J Eron, John W Mellors, ACTG A5321 Team   +13 more
doaj   +2 more sources

HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir [PDF]

Communications Medicine
Background Relatively few studies have investigated HIV-1 persistence in tissues, especially in healthy people-living-with-HIV-1 (PLWH) on a successful antiretroviral regimen containing second generation integrase inhibitors.
Gilbert Mchantaf, Adeline Melard, Kévin Da Silva, Elise Gardiennet, Antoine Chaillon, Bénédicte Lefebvre, Jade Ghosn, Olivier Robineau, Jean-Paul Viard, Lucie Adoux, Frédéric Lemoine, Aurélie Barrail-Tran, Sylvie Orr, Fatoumata Coulibaly, Laurence Meyer, Antoine Cheret, Véronique Avettand-Fenoel   +16 more
doaj   +2 more sources

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms [PDF]

Frontiers in Microbiology, 2019
HIV-1 viremia persists at low-levels despite clinically effective antiretroviral therapy (ART). Here we review new methods to quantify and characterize persistent viremia at the single genome level, and discuss the mechanisms of persistence including ...
Jana L. Jacobs, Elias K. Halvas, Melissa A. Tosiano, John W. Mellors   +3 more
doaj   +3 more sources

Persistent HIV-1 replication during antiretroviral therapy [PDF]

Current Opinion in HIV and AIDS, 2016
The present review will highlight some of the recent findings regarding the capacity of HIV-1 to replicate during antiretroviral therapy (ART).Although ART is highly effective at inhibiting HIV replication, it is not curative. Several mechanisms contribute to HIV persistence during ART, including HIV latency, immune dysfunction, and perhaps persistent ...
Martinez-Picado, Javier, Deeks, Steven G
  +10 more sources

Hiding in plain sight – platelets, the silent carriers of HIV-1

Platelets, 2021
There are approximately 38 million people globally living with Human immunodeficiency virus 1 (HIV-1) and given the tremendous success of combination antiretroviral therapy (cART) this has dramatically reduced mortality and morbidity with prevention ...
Yvonne Baumer, Tina M. Weatherby, Brooks I. Mitchell, Ivo N. SahBandar, Thomas A. Premeaux, D’Antoni Michelle L., Cristhian A. Gutierrez-Huerta, Tiffany M. Powell-Wiley, Timothy R. Brown, William A. Boisvert, Cecilia M. Shikuma, Lishomwa C. Ndhlovu   +11 more
doaj   +1 more source

Persistence of HIV-1 Transmitted Drug Resistance Mutations [PDF]

The Journal of Infectious Diseases, 2013
There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive.
Castro, H., Pillay, D., Cane, P., Asboe, D., Cambiano, V., Phillips, A., Dunn, D. T., Aitken, C., Asboe, D., Webster, D., Cane, P., Castro, H., Chadwick, D., Churchill, D., Clark, D., Collins, S., Delpech, V., Geretti, A. M., Goldberg, D., Hale, A., Hue, S., Kaye, S., Kellam, P., Lazarus, L., Leigh-Brown, A., Mackie, N., Orkin, C., Rice, P., Pillay, D., Smit, E., Templeton, K., Tilston, P., Tong, W., Williams, I., Zhang, H., Zuckerman, M., Greatorex, J., Wildfire, A., O'Shea, S., Mullen, J., Mbisa, T., Cox, A., Tandy, R., Hale, T., Fawcett, T., Hopkins, M., Ashton, L., Garcia-Diaz, A., Shepherd, J., Schmid, M. L., Payne, B., Chadwick, D., Hay, P., Rice, P., Paynter, M., Clark, D., Bibby, D., Kaye, S., Kirk, S., MacLean, A., Aitken, C., Gunson, R.   +61 more
openaire   +5 more sources

Latency and viral persistence in HIV-1 infection [PDF]

Journal of Clinical Investigation, 2000
HIV-1 infection can be controlled with combinations of antiretroviral drugs, an approach known as highly active antiretroviral therapy (HAART). In patients who respond well to HAART, viremia decreases to below the limits of detection, disease progression stops, and reconstitution of the immune system begins.
J D, Siliciano, R F, Siliciano
openaire   +2 more sources